Novartis agreed to acquire an experimental breast-cancer drug from Synnovation Therapeutics for up to $3 billion.
: Analysts maintain an Overweight rating , forecasting significant upside potential. If you're looking for more info, are you interested in: Specific types of cancer treatments (like CAR-T or ADCs)? Financial analysis of these stocks? Clinical trial details for these new acquisitions? buy cancer
: Abbott's $21B move for Exact Sciences highlights a growing market for early detection through blood and stool tests. Investment Outlook buy cancer
Major pharmaceutical companies have been on a massive spending spree in 2025 and 2026, acquiring innovative biotech firms to bolster their cancer-treatment pipelines. buy cancer